The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Multi-Target Drugs: The Trend of Drug Research and Development
Open accessAbstract
Summarizing the status of drugs in the market and examining the trend of drug research and development is important in drug discovery. In this study, we compared the drug targets and the market sales of the new molecular entities approved by the U.S. Food and Drug Administration from January 2000 to December 2009. Two networks, namely, the target-target and drug-drug networks, have been set up using the network analysis tools. The multi-target drugs have much more potential, as shown by the network visualization and the market trends. We discussed the possible reasons and proposed the rational strategies for drug research and development in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural products in drug discovery
Harvey, A. L. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.07.004 · Cited by 1,832
Yıldırım, M. A., Goh, K.-I., Cusick, M. E., Barabási, A.-L., & Vidal, M. (2007) · Nature Biotechnology · doi:10.1038/nbt1338 · Cited by 1,708
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Discovery of curcumin, a component of golden spice, and its miraculous biological activities
Gupta, S. C., Patchva, S., Koh, W., & Aggarwal, B. B. (2012) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2011.05648.x · Cited by 856
Gupta, S. C., Kim, J. H., Prasad, S., & Aggarwal, B. B. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9235-2 · Cited by 806
The efficiency of multi-target drugs: the network approach might help drug design
CSERMELY, P., AGOSTON, V, & PONGOR, S. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.02.007 · Cited by 803
Multitargeting by curcumin as revealed by molecular interaction studies
Gupta, S. C., Prasad, S., Kim, J. H., Patchva, S., Webb, L. J., Priyadarsini, I. K., & Aggarwal, B. B. (2011) · Natural Product Reports · doi:10.1039/c1np00051a · Cited by 669
Gong, C.-X., & Iqbal, K. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785909111 · Cited by 644
AMPK and cell proliferation – AMPK as a therapeutic target for atherosclerosis and cancer
Motoshima, H., Goldstein, B. J., Igata, M., & Araki, E. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2006.108324 · Cited by 527
From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
Giordano, S., & Petrelli, A. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708783503212 · Cited by 457
A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs
Sun, Y., Xun, K., Wang, Y., & Chen, X. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328330d95b · Cited by 417
Self-citationAnti-cancer natural products isolated from chinese medicinal herbs
Tan, W., Lu, J., Huang, M., Li, Y., Chen, M., Wu, G., Gong, J., Zhong, Z., Xu, Z., Dang, Y., et al. (2011) · Chinese Medicine · doi:10.1186/1749-8546-6-27 · Cited by 396
Self-citationSystems approaches to polypharmacology and drug discovery.
Boran, A. D. W., & Iyengar, R. (2010) · PubMed · Cited by 339
Frantz, S. (2005) · Nature · doi:10.1038/437942a · Cited by 322
Bolognesi, M. L., Cavalli, A., Valgimigli, L., Bartolini, M., Rosini, M., Andrisano, V., Recanatini, M., & Melchiorre, C. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm701225u · Cited by 260
Gökhan-Kelekçi, N., Yabanoğlu, S., Küpeli, E., Salgın, U., Özgen, Ö., Uçar, G., Yeşilada, E., Kendi, E., Yeşilada, A., & Bilgin, A. A. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.06.004 · Cited by 229
Combination Therapy in Alzheimer???s Disease: A Review of Current Evidence
Schmitt, B., Bernhardt, T., Moeller, H.-J., Heuser, I., & Fr??lich, L. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00001 · Cited by 182
The 26S proteasome complex: An attractive target for cancer therapy
Frankland-Searby, S., & Bhaumik, S. R. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.10.003 · Cited by 173
The mTOR Pathway: A New Target in Cancer Therapy
Ciuffreda, L., Di Sanza, C., Incani, U. C., & Milella, M. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791517172 · Cited by 170
Current status of SRC inhibitors in solid tumor malignancies
Puls, L. N., Eadens, M., & Messersmith, W. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0408 · Cited by 158
Schapira, A. H. V. (2011) · CNS Drugs · doi:10.2165/11596310-000000000-00000 · Cited by 153
Glisson, B. S., & Ross, W. E. (1987) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(87)90054-4 · Cited by 144
Wei, D., Jiang, X., Zhou, L., Chen, J., Chen, Z., He, C., Yang, K., Liu, Y., Pei, J., & Lai, L. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8010096 · Cited by 141
Srinivas, N. R. (2010) · Xenobiotica · doi:10.3109/00498251003663724 · Cited by 135
Zhu, Y., Xiao, K., Ma, L., Xiong, B., Fu, Y., Yu, H., Wang, W., Wang, X., Hu, D., Peng, H., et al. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.12.067 · Cited by 109
Focal Adhesion Kinase as a Cancer Therapy Target
Golubovskaya, V. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152010794728648 · Cited by 105
Combination Therapy for Alzheimerʼs Disease
Patel, L., & Grossberg, G. T. (2011) · Drugs & Aging · doi:10.2165/11591860-000000000-00000 · Cited by 103
Canta, A., Chiorazzi, A., & Cavaletti, G. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787846488 · Cited by 102
Zhang, H., Jia, H., Liu, J., Ao, N., Yan, B., Shen, W., Wang, X., Li, X., Luo, C. Y., & Liu, J. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00390.x · Cited by 89
Targeting EGFR in non-small-cell lung cancer: Lessons, experiences, strategies
Stella, G. M., Luisetti, M., Inghilleri, S., Cemmi, F., Scabini, R., Zorzetto, M., & Pozzi, E. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2011.10.015 · Cited by 85
Navarra, T., Turco, S. D., Berti, S. L., & Basta, G. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.3228 · Cited by 76
Multifocal signal modulation therapy of cancer: ancient weapon, modern targets
Das, T., Sa, G., Saha, B., & Das, K. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0269-0 · Cited by 67
Zheng, H., Amit, T., Bar‐Am, O., Fridkin, M., Youdim, M. B. H., & Mandel, S. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120013 · Cited by 65
Ament, Z., Masoodi, M., & Griffin, J. L. (2012) · Genome Medicine · doi:10.1186/gm331 · Cited by 63
Chang, C. C. Y., Dong, R., Miyazaki, A., Sakashita, N., Zhang, Y., Liu, J., Guo, M., Li, B.-L., & Chang, T. (2006) · Acta Biochimica et Biophysica Sinica · doi:10.1111/j.1745-7270.2006.00154.x · Cited by 57
Histone Deacetylation: An Attractive Target for Cancer Therapy?
Al-Janadi, A., Chandana, S. R., & Conley, B. A. (2008) · Drugs in R&D · doi:10.2165/0126839-200809060-00003 · Cited by 39
Zhou, Y., Chen, Y., Tong, L., Xie, H., Wen, W., Zhang, J., Xi, Y., Shen, Y., Geng, M., Wang, Y., et al. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2012.01541.x · Cited by 33
Self-citationPeroxisome Proliferator-Activated Receptors and Atherosclerosis
Šoškić, S., Dobutović, B., Sudar-Milovanovic, E. M., Obradovic, M. M., Nikolić, D., Zarić, B. L., Stojanović, S. Đ., Stokić, E., Mikhailidis, D. P., & Isenović, E. R. (2011) · Angiology · doi:10.1177/0003319711401012 · Cited by 32
Antoniu, S. A., & Kolb, M. R. J. (2010) · PubMed · Cited by 31
Nilotinib: A Phenylamino-Pyrimidine Derivative with Activity Against BCR-ABL, KIT and PDGFR Kinases
Quintás‐Cardama, A., & Cortes, J. E. (2008) · Future Oncology · doi:10.2217/14796694.4.5.611 · Cited by 25
Combinatorial Effect of Probucol and Cilostazol in Focal Ischemic Mice with Hypercholesterolemia
Kim, J. H., Park, S. H., Bae, S. S., Hong, K. W., Kim, Y. D., Park, K., Choi, B. T., & Shin, H. K. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.181180 · Cited by 18
[Modification of natural products for drug discovery].
Guo, Z. (2012) · PubMed · Cited by 17
Gamma-Secretase as a Pharmacological Target in Alzheimer Disease Research: When, Why and How?
Ziani‐Cherif, C., Mostefa‐Kara, B., & Brixi-Gormat, F. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778792994 · Cited by 13
Utility of Atherosclerosis Imaging in the Evaluation of High-Density Lipoprotein–Raising Therapies
Duivenvoorden, R., & Fayad, Z. A. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0176-1 · Cited by 11
Targeting Strategies for Human Immunodeficiency Virus: A Combinatorial Approach
Saxena, S. K., Gupta, A., Bhagyashree, K., Saxena, R., Arora, N., Banerjee, A., Tripathi, A. K., Chandrasekar, M., Gandhi, N. H., & Nair, M. (2012) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557511209030236 · Cited by 10
Cited by
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Polypharmacology: Challenges and Opportunities in Drug Discovery: Miniperspective
Anighoro, A., Bajorath, J., & Rastelli, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006463 · Cited by 1,131
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892
A perspective on multi‐target drug discovery and design for complex diseases
Ramsay, R. R., Popovic‐Nikolic, M. R., Nikolic, K., Uliassi, E., & Bolognesi, M. L. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0181-2 · Cited by 718
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
Metadata
- Authors
- Lu, J.-J., Pan, W., Hu, Y.-J., & Wang, Y.-T.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-06-29
- Volume
- 7
- Issue
- 6
- Pages
- e40262
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2063906445
- Cited by
- 259
- References
- 45
- FWCI
- 24.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.